New Data Buoy Takeda/Seattle Genetics’ Confidence In Adcetris
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical and Seattle Genetics have announced new top-line results from the Phase III AETHERA trial with Adcetris in Hodgkin lymphoma that pave the way for a FDA supplementary regulatory filing in this setting sometime next year.